Tech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Neurizon Therapeutics.
RELATED STOCKHEAD STORIES
Health & Biotech
PharmAust headed for a ‘Who’s a Good Boy?’ as positive Monepantel canine trials progress
Health & Biotech
PharmAust and FightMND band together to fight against Motor Neurone Disease
Health & Biotech
PharmAust’s subsidiary Epichem appoints new GM as it sets eyes on new commercial opportunities
Health & Biotech
PharmAust accelerates MPL clinical trials in fights against Covid and Motor Neuron Disease
Health & Biotech
PharmAust inks deal with Radium Capital to bag up-front R&D tax claim
Health & Biotech
PharmAust set for Phase 1 Motor Neurone Disease trial as Monepantel tablets arrive
News
Market Highlights and 5 ASX Small Caps to watch on Monday
Health & Biotech
PharmAust expands canine trial of Monepantel to the US, expediting the close out of Phase 2 study
News
Meet the pain: Eddy quaffed all these small cap quarterlies and we saved you the best bits
Health & Biotech
PharmAust confirms cash boost for Phase 1 trials, with ATO approval for federal R&D refund
Health & Biotech
Bring it on: PharmAust to start Phase 1 trial after first instalment lands from FightMND
Health & Biotech
Similarities with our pets could offer giant breakthroughs in cancer research, says PharmAust
Health & Biotech
PharmAust ships first batch of MPL to the US, gets ready for two upcoming clinical trials
News
Market Highlights and 5 ASX Small Caps to watch on Tuesday
Health & Biotech
Preliminary results show PharmAust’s monepantel drug is effective against leukaemia virus HTLV-1
Health & Biotech
PharmAust gets massive expertise boost as final preparations begin for COVID-19 clinical trial
Health & Biotech
